On May 7, 2021 Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, reported that its President and Chief Executive Officer, Christopher U. Missling, PhD, will give a presentation titled, "Clinical Trials for Rare Diseases: Challenges and Opportunities", at the Precision in Clinical Trials Virtual Summit (East Coast) on Monday, May 10that 9:35 a.m. EDT (Press release, Anavex Life Sciences, MAY 7, 2021, View Source [SID1234579429]). The Precision in Clinical Trials Virtual Summit (East Coast) takes place May 10th – 11th 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!